clinical trial · NCT05135559
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
Novo Nordisk A/S·phase3·active not recruiting·n = 153
Haemophilia A and B With and Without InhibitorsConcizumab
brief summary
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin with a pen-injector. The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.
started
Mar 24, 2022
primary completion
Apr 21, 2026
completion
Nov 2, 2029
last updated
Dec 30, 2025
official title
Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol